Compare 3M Company (MMM) vs Novavax Inc (NVAX) Price & Performance

3M (MMM) trades at $159.96, down 1.33% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.40 versus $2.25 expected, and maintains a robust net income margin of 11.9%. Recent news highlights operational momentum, including raised guidance and progress on litigation management. Cash flow from operations improved to $2.31 billion in 2025, though net cash flow was negative $319 million due to financing activities.

The outlook is mixed; analyst consensus is a Buy with a $191 price target, implying 19% upside, but technical indicators suggest near-term pressure. Key risks include high debt levels, weak consumer segment demand, and cost pressures. Earnings growth and margin expansion remain critical for sustained stock appreciation amid competitive and macroeconomic challenges.

Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.